Glioblastoma Multiforme (GBM) Market in 8MM – Market Outlook, Unmet Needs, Market Assessment and Forecast (2023-2030)

Glioblastoma Multiforme (GBM) Market – Report Overview

Pacific Business Consulting’s “Glioblastoma Multiforme (GBM) Market in 8MM – Market Outlook, Unmet Needs, Market Assessment and Forecast (2023-2030)” report offers a comprehensive understanding of Glioblastoma Multiforme (GBM), encompassing historical and projected market size data, along with market trends, market drivers, market barriers and unmet medical needs in the Eight Major Markets (8MM) of the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and China.

The market size of Glioblastoma Multiforme (GBM) in the eight major markets reached an estimated US$1.3 billion in 2022, with the United States contributing nearly 65% of this total among the eight covered countries.

Glioblastoma is a malignant brain tumor originating from astrocytes, a specific type of brain cell. These tumors are aggressive, infiltrating surrounding brain tissue, and unfortunately, there is no cure for GBM. Treatment for glioblastoma is challenging due to varied responses of different cells to therapies. Therefore, treatment plans often involve a combination of approaches, such as surgery, chemotherapy, radiation, or stereotactic radiosurgery, followed by additional/adjuvant treatments like chemotherapy or radiation therapy after surgery. The goal of treatment is palliative, aiming to alleviate symptoms and improve quality of life.

In April 2005, the FDA approved Temodar capsules (temozolomide) for concurrent use with radiotherapy for adults with newly diagnosed GBM and as maintenance therapy after radiotherapy. Additionally, in December 2017, bevacizumab (Avastin) received full FDA approval for the treatment of adults with recurrent glioblastoma that has progressed following prior therapy. In the European and Japanese markets, only Temodar has been approved by the EMA and MHLW, respectively, for the treatment of patients with GBM.

The GBM pipeline is robust with multiple potential drugs in late and mid-stage development. The pipeline includes drugs with diverse mechanisms of action and various routes of administration, including oral, intravenous, intratumoral, and subcutaneous. Notably, emerging treatments include gene therapy (Ofranergene obadenovec by VBL Therapeutics) and vaccine/immunotherapy candidates (VBI-1901, AV-Glioblastoma Multiforme-1, ITI-1000 by VBI Vaccines, Aivita Biomedical, Immunomic Therapeutics, and DNAtrix).

Promising candidates in late- and mid-phase clinical development include Ofranergene obadenovec (VB-111; VBL Therapeutics), Tasadenoturev (DNX-2401; DNAtrix), ONC201 (Chimerix), Selinexor (KPT-330; Karyopharm Therapeutics), VBI-1901 (VBI Vaccines), Paxalisib (GDC-0084; Kazia Therapeutics), AV-Glioblastoma Multiforme-1 (Aivita Biomedical), Regorafenib (Bayer), and others.

Scope of Report

The report addresses critical subjects such as strategic competitor evaluation, market characterization, unmet needs, and the consequences of these elements for the Glioblastoma Multiforme market. It also delves into the analysis of present and prospective market competition within the global Glioblastoma Multiforme market.

Furthermore, the report offers an insightful examination of the primary industry drivers, constraints, and challenges. Each trend undergoes independent research to furnish qualitative analysis regarding its implications.

Reasons to Buy

• Develop your business strategies by gaining insights into the trends that shape and drive the Glioblastoma Multiforme market across the 8MM (Eight Major Markets).
• Increase revenue by comprehending key trends, innovative products and technologies, market segments, and companies poised to influence the future of the 8MM Glioblastoma Multiforme market.
• Craft effective sales and marketing strategies by thoroughly understanding the competitive landscape and analyzing the performance of various competitors.
• Identify emerging players with potentially robust product portfolios and devise strategic counter-strategies to gain a competitive advantage.
• Optimize your sales and marketing efforts by pinpointing market categories and segments that offer the greatest opportunities for consolidations, investments, and strategic partnerships.

Please note that detailed pipeline analysis can be provided along with the standard scope to assist you in developing and designing your in-licensing and out-licensing strategies. This includes a review of pipeline products and technologies, along with identifying companies with the most robust pipeline.

1. Executive Summary: Glioblastoma Multiforme (GBM)
   • Global Market Outlook: Glioblastoma Multiforme (GBM)
2. Competitive Intelligence Analysis: Glioblastoma Multiforme (GBM)
3. Therapeutic Sector SWOT
4. Technology Roadmap Analysis: Glioblastoma Multiforme (GBM)
5. Market Background
   • Drivers
   • Restraints
   • Opportunity
   • Key Market Trends
   • Key Unmet Needs
6. Disease Overview: Glioblastoma Multiforme (GBM)
   • Disease Etiology
   • Pathophysiology
   • Risk Factors
   • Treatment Algorithm
7. Glioblastoma Multiforme (GBM): Key Marketed Products Profile – Major Approved Products
   • Product Profile
   • Regulatory Milestones
   • Safety and Efficacy
   • Clinical Development
8. Glioblastoma Multiforme (GBM): Promising Pipeline Candidates – Major Products in Late Stage of Development
   • Product Description
   • Safety and Efficacy
   • Research and Development
9. Regulatory Landscape
10. Glioblastoma Multiforme (GBM): Eight Major Market (8MM) – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
    • Current and Future Market Projections (US$ million), 2023-2030
11. S. Glioblastoma Multiforme (GBM) – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
    • Current and Future Market Projections (US$ million), 2023-2030
12. K. Glioblastoma Multiforme (GBM) – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
    • Current and Future Market Projections (US$ million), 2023-2030
13. Germany Glioblastoma Multiforme (GBM) – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
    • Current and Future Market Projections (US$ million), 2023-2030
14. France Glioblastoma Multiforme (GBM) – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
    • Current and Future Market Projections (US$ million), 2023-2030
15. Italy Glioblastoma Multiforme (GBM) – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
    • Current and Future Market Projections (US$ million), 2023-2030
16. Spain Glioblastoma Multiforme (GBM) – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
    • Current and Future Market Projections (US$ million), 2023-2030
17. Japan Glioblastoma Multiforme (GBM) – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
    • Current and Future Market Projections (US$ million), 2023-2030
18. China Glioblastoma Multiforme (GBM) – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
    • Current and Future Market Projections (US$ million), 2023-2030
19. Competitive Landscape
    • Company Overview
    • Product Portfolio
    • Key Financials
    • Sales Footprint

Note – All Major Company Profiles (Count up to 20) will be covered in the report

20. Assumptions and Acronyms Used
21. Research Methodology
    • Secondary Research
    • Primary Research
    • Data Triangulation
22. Geographic Scope
    • The U.S., The U.K., Germany, France, Italy, Spain, Japan, and China
23. Copyrights and Disclaimer